Chagas

FEXI 12

Oral fexinidazole dosing regimens for the treatment of adults with chronic indeterminate Chagas disease

Foto: DNDi
Duración
04/10/2017 - 31/12/2018
Coordinador
Joaquim Gascon
Financiadores
DNDi

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study

The general objective of this clinical trial is to determine the efficacy and safety of alternative dosing regimens of FEXI in reducing and clearing T. cruzi parasitemia in adult individuals with the chronic indeterminate Chagas Disease, in comparison to historical placebo control.

This is  a double-blind, randomized, prospective, comparative, pharmacokineticpharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control. The trial will be conducted in 5 different sites in Spain. The trial will be sufficiently powered to compare the efficacy and safety of each of the dosing regimens of FEXI with historical placebo control. Efficacy and safety will be monitored by an external independent Data Monitoring Committee (DMC) on an ongoing basis. The committee is to include cardiac and liver safety experts, as well as Chagas Disease clinical expertise.

The total duration of patient trial participation will be approximately 14 months.

Nuestro equipo

PI

  • Joaquim Gascon
    Joaquim Gascon Research Professor, Director de la Iniciativa de Chagas y del programa de Chagas y Enfermedades Parasitarias e Importadas

ISGlobal team

Ver más

Otros proyectos

Ver proyectos pasados

NHEPACHA

Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

TcONTROL

Biomarcadores inmunológicos antígeno-específicos (células T) asociados al control de la infección por T. cruzi

XStrategy

Modelo y Herramienta para la construcción de estrategias para el incremento de la atención en Chagas

TESEO

Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.